Skip to main content

Disclaimer

In the Downloads section, the ‘Prior Submission’ file reflects the most recent measure submission to the former CBE. This file is provided for transparency. For any questions or clarification, please contact the designated measure steward.

Non-Diabetic Nephropathy - Use of ACE Inhibitor or ARB Therapy

CBE ID
0621
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

The percentage of patients aged 18 years and older with proteinuria who are taking an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      No
      1.9 Care Setting
      1.14 Numerator

      Patients with a current fill for an ACE-I or ARB

      1.15 Denominator

      All patients aged 18 years and older with a urine protein >= 200 mg/g

      Exclusions

      Specific exclusions:
      Patients with contraindication to an ACE inhibitor or ARB, including pregnancy, prior angioedema, hypotension, hyperkalemia, rising creatinine, chronic kidney disease stage 3-5 (without dialysis), aortic stenosis, hypertrophic cardiomyopathy, multiple myeloma with treatment, diabetes diagnosis, renal transplant, immunosuppresive therapy
      Patient data confirming pregnancy/delivery, pregnancy planning, breastfeeding, hypotension, or refill for Aliskiren in the past 6 months

      General exclusions:
      • Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
      • Patients who have been in a skilled nursing facility in the last 3 months

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Renal Endorsement Maintenance Project
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      ActiveHealth Management
      Steward POC email
                Public Comments